Exchange Traded Concepts’s Myriad Genetics MYGN Stock Holding History

Exchange Traded Concepts’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-7,072	Closed	-$103K	–	1232
2022 Q4	$103K	Buy	7,072 +2,116	+43%	+$39.4K	﹤0.01%	759
2022 Q3	$95K	Buy	4,956 +1,368	+38%	+$31.4K	﹤0.01%	757
2022 Q2	$65K	Buy	3,588 +2,455	+217%	+$51K	﹤0.01%	866
2022 Q1	$29K	Buy	+1,133	New	+$29K	﹤0.01%	992
2020 Q1	–	Sell	-3,123	Closed	-$85K	–	570
2019 Q4	$85K	Buy	+3,123	New	+$85.9K	0.02%	220

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Exchange Traded Concepts's MYGN Position: Q1 2023 in Review

Exchange Traded Concepts sold out of Myriad Genetics (MYGN) in Q1 2023, closing a stake of 7,072 shares — an estimated $103K sold.

Exchange Traded Concepts first reported a position in MYGN in Q4 2019 and held it in 5 quarters. The position peaked at $103K in Q4 2022. 190 funds tracked by Wall St. Rank hold MYGN as of Q1 2023.

Exchange Traded Concepts reported no remaining Myriad Genetics position as of Q1 2023 after selling out during the quarter.
Exchange Traded Concepts sold 7,072 Myriad Genetics shares in Q1 2023, an estimated $103K.
Exchange Traded Concepts first reported a position in Myriad Genetics in Q4 2019 and held it in 5 quarters.
Exchange Traded Concepts's Myriad Genetics position peaked at $103K in Q4 2022.
190 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2023.

Based on Exchange Traded Concepts's 13F filing for Q1 2023, filed 12 Apr 2023.